608 related articles for article (PubMed ID: 7777568)
1. Cytotoxic T-lymphocyte clones from different patients display limited T-cell-receptor variable-region gene usage in HLA-A2-restricted recognition of the melanoma antigen Melan-A/MART-1.
Sensi M; Traversari C; Radrizzani M; Salvi S; Maccalli C; Mortarini R; Rivoltini L; Farina C; Nicolini G; Wölfel T
Proc Natl Acad Sci U S A; 1995 Jun; 92(12):5674-8. PubMed ID: 7777568
[TBL] [Abstract][Full Text] [Related]
2. T cell receptor (TCR) structure of autologous melanoma-reactive cytotoxic T lymphocyte (CTL) clones: tumor-infiltrating lymphocytes overexpress in vivo the TCR beta chain sequence used by an HLA-A2-restricted and melanocyte-lineage-specific CTL clone.
Sensi M; Salvi S; Castelli C; Maccalli C; Mazzocchi A; Mortarini R; Nicolini G; Herlyn M; Parmiani G; Anichini A
J Exp Med; 1993 Oct; 178(4):1231-46. PubMed ID: 8376931
[TBL] [Abstract][Full Text] [Related]
3. Large and dissimilar repertoire of Melan-A/MART-1-specific CTL in metastatic lesions and blood of a melanoma patient.
Mandruzzato S; Rossi E; Bernardi F; Tosello V; Macino B; Basso G; Chiarion-Sileni V; Rossi CR; Montesco C; Zanovello P
J Immunol; 2002 Oct; 169(7):4017-24. PubMed ID: 12244204
[TBL] [Abstract][Full Text] [Related]
4. Overlapping peptides of melanocyte differentiation antigen Melan-A/MART-1 recognized by autologous cytolytic T lymphocytes in association with HLA-B45.1 and HLA-A2.1.
Schneider J; Brichard V; Boon T; Meyer zum Büschenfelde KH; Wölfel T
Int J Cancer; 1998 Jan; 75(3):451-8. PubMed ID: 9455808
[TBL] [Abstract][Full Text] [Related]
5. The majority of autologous cytolytic T-lymphocyte clones derived from peripheral blood lymphocytes of a melanoma patient recognize an antigenic peptide derived from gene Pmel17/gp100.
Zarour H; De Smet C; Lehmann F; Marchand M; Lethé B; Romero P; Boon T; Renauld JC
J Invest Dermatol; 1996 Jul; 107(1):63-7. PubMed ID: 8752841
[TBL] [Abstract][Full Text] [Related]
6. Cytolytic T-cell clones define HLA-A2-restricted human cutaneous melanoma peptide epitopes: correlation with T-cell receptor usage.
Maeurer MJ; Hurd S; Martin DM; Storkus WJ; Lotze MT
Cancer J Sci Am; 1995; 1(2):162-70. PubMed ID: 9166469
[TBL] [Abstract][Full Text] [Related]
7. Prevalent role of TCR alpha-chain in the selection of the preimmune repertoire specific for a human tumor-associated self-antigen.
Dietrich PY; Le Gal FA; Dutoit V; Pittet MJ; Trautman L; Zippelius A; Cognet I; Widmer V; Walker PR; Michielin O; Guillaume P; Connerotte T; Jotereau F; Coulie PG; Romero P; Cerottini JC; Bonneville M; Valmori D
J Immunol; 2003 May; 170(10):5103-9. PubMed ID: 12734356
[TBL] [Abstract][Full Text] [Related]
8. Cytolytic T lymphocyte recognition of the immunodominant HLA-A*0201-restricted Melan-A/MART-1 antigenic peptide in melanoma.
Romero P; Gervois N; Schneider J; Escobar P; Valmori D; Pannetier C; Steinle A; Wolfel T; Lienard D; Brichard V; van Pel A; Jotereau F; Cerottini JC
J Immunol; 1997 Sep; 159(5):2366-74. PubMed ID: 9278327
[TBL] [Abstract][Full Text] [Related]
9. T-cell receptor usage by melanoma-specific clonal and highly oligoclonal tumor-infiltrating lymphocyte lines.
Shilyansky J; Nishimura MI; Yannelli JR; Kawakami Y; Jacknin LS; Charmley P; Rosenberg SA
Proc Natl Acad Sci U S A; 1994 Mar; 91(7):2829-33. PubMed ID: 7511820
[TBL] [Abstract][Full Text] [Related]
10. Dual recognition of a human cytotoxic T-cell clone for melanoma antigens.
Kubo H; Abe J; Obata F; Nakajima H; Tsunoda M; Ogawa A; Nakayama S; Beck Y; Kohsaka T; Darrow TL; Abdel-Wahab Z; Saida T; Takiguchi M
Cancer Res; 1996 May; 56(10):2368-74. PubMed ID: 8625313
[TBL] [Abstract][Full Text] [Related]
11. Cytotoxic T cells directed to tumor antigens not expressed on normal melanocytes dominate HLA-A2.1-restricted immune repertoire to melanoma.
Anichini A; Mortarini R; Maccalli C; Squarcina P; Fleischhauer K; Mascheroni L; Parmiani G
J Immunol; 1996 Jan; 156(1):208-17. PubMed ID: 8598464
[TBL] [Abstract][Full Text] [Related]
12. Identification of a public CDR3 motif and a biased utilization of T-cell receptor V beta and J beta chains in HLA-A2/Melan-A-specific T-cell clonotypes of melanoma patients.
Serana F; Sottini A; Caimi L; Palermo B; Natali PG; Nisticò P; Imberti L
J Transl Med; 2009 Mar; 7():21. PubMed ID: 19317896
[TBL] [Abstract][Full Text] [Related]
13. Peptide-specific CTL in tumor infiltrating lymphocytes from metastatic melanomas expressing MART-1/Melan-A, gp100 and Tyrosinase genes: a study in an unselected group of HLA-A2.1-positive patients.
Spagnoli GC; Schaefer C; Willimann TE; Kocher T; Amoroso A; Juretic A; Zuber M; Luscher U; Harder F; Heberer M
Int J Cancer; 1995 Oct; 64(5):309-15. PubMed ID: 7591302
[TBL] [Abstract][Full Text] [Related]
14. Cytotoxic T lymphocytes define multiple peptide isoforms derived from the melanoma-associated antigen MART-1/Melan-A.
Jäger E; Höhn H; Karbach J; Momburg F; Castelli C; Knuth A; Seliger B; Maeurer MJ
Int J Cancer; 1999 Jun; 81(6):979-84. PubMed ID: 10362148
[TBL] [Abstract][Full Text] [Related]
15. Identification of MART-1-specific T-cell receptors: T cells utilizing distinct T-cell receptor variable and joining regions recognize the same tumor epitope.
Cole DJ; Weil DP; Shamamian P; Rivoltini L; Kawakami Y; Topalian S; Jennings C; Eliyahu S; Rosenberg SA; Nishimura MI
Cancer Res; 1994 Oct; 54(20):5265-8. PubMed ID: 7522957
[TBL] [Abstract][Full Text] [Related]
16. Quantitative correlation between HLA class I allele expression and recognition of melanoma cells by antigen-specific cytotoxic T lymphocytes.
Rivoltini L; Barracchini KC; Viggiano V; Kawakami Y; Smith A; Mixon A; Restifo NP; Topalian SL; Simonis TB; Rosenberg SA
Cancer Res; 1995 Jul; 55(14):3149-57. PubMed ID: 7541714
[TBL] [Abstract][Full Text] [Related]
17. Recognition of shared melanoma antigen by HLA-A2-restricted cytolytic T cell clones derived from human tumor-infiltrating lymphocytes.
Viret C; Davodeau F; Guilloux Y; Bignon JD; Semana G; Breathnach R; Jotereau F
Eur J Immunol; 1993 Jan; 23(1):141-6. PubMed ID: 8419164
[TBL] [Abstract][Full Text] [Related]
18. Melanoma cells and normal melanocytes share antigens recognized by HLA-A2-restricted cytotoxic T cell clones from melanoma patients.
Anichini A; Maccalli C; Mortarini R; Salvi S; Mazzocchi A; Squarcina P; Herlyn M; Parmiani G
J Exp Med; 1993 Apr; 177(4):989-98. PubMed ID: 8459226
[TBL] [Abstract][Full Text] [Related]
19. Culture of melanoma cells in 3-dimensional architectures results in impaired immunorecognition by cytotoxic T lymphocytes specific for Melan-A/MART-1 tumor-associated antigen.
Ghosh S; Rosenthal R; Zajac P; Weber WP; Oertli D; Heberer M; Martin I; Spagnoli GC; Reschner A
Ann Surg; 2005 Dec; 242(6):851-7, discussion 858. PubMed ID: 16327495
[TBL] [Abstract][Full Text] [Related]
20. Melanoma patients respond to a cytotoxic T lymphocyte-defined self-peptide with diverse and nonoverlapping T-cell receptor repertoires.
Dietrich PY; Walker PR; Quiquerez AL; Perrin G; Dutoit V; Liénard D; Guillaume P; Cerottini JC; Romero P; Valmori D
Cancer Res; 2001 Mar; 61(5):2047-54. PubMed ID: 11280765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
